ASCO 2020: Researchers underscore efficacy of pembrolizumab plus

Researchers at Fox Chase Cancer Center, along with an international team of investigators, have found that the use of pembrolizumab in combination with axiti

Full article: Personalizing immunotherapy for renal cell carcinoma: how far have we come?

MicroRNAs as regulators of immune checkpoints in cancer immunotherapy: targeting PD-1/PD-L1 and CTLA-4 pathways, Cancer Cell International

ASCO GU 2023: Pembrolizumab plus Docetaxel for Patients with mCRPC: Randomized, Double-Blind, Phase 3 KEYNOTE-921 Study

2022 ASCO® Annual Meeting: Updates on the Treatment of Advanced Renal Cell Carcinoma - Cancer Therapy Advisor

PDF) Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%

Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma

Targeting HER2-positive breast cancer: advances and future directions

Cancers, Free Full-Text

Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%

ASCO GU 2022: Randomized Comparator-Controlled Study Evaluating Efficacy and Safety of Pembrolizumab plus BCG in Patients with High-Risk Nonmuscle-Invasive Bladder Cancer: KEYNOTE-676 Cohort B